Sandoz Sanguine On Market Opportunity Despite Biosimilar Neulasta Setback

 
• By Lucie Ellis-Taitt
  
Illustration of an European Union long shadow flag with a weight scale
Sandoz withdraws European marketing application for biosimilar pegfilgrastim • Source: Shutterstock

More from New Products

More from Scrip